 |
|
Screening for Statin-Related Toxicity
The Yield of Transaminase and Creatine Kinase Measurements in a Primary Care Setting
C. Christopher Smith, MD;
Lana I. Bernstein, MD;
Roger B. Davis, ScD;
David M. Rind, MD;
Robert H. Shmerling, MD
Arch Intern Med. 2003;163:688-692.
Background Recommendations for monitoring levels of transaminases (alanine aminotransferase and aspartate aminotransferase) and of creatine kinase (CK) in patients taking 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) vary and are not based on data from clinical practice. We performed a study to determine the yield of routine screening of aminotransferase and CK levels among patients taking statins.
Methods We performed a retrospective review of a primary care practice's computerized medical record. A computerized search identified all patients with a statin on their medication list and gave their alanine aminotransferase, aspartate aminotransferase, and CK values for 1998. We reviewed the records of all patients for whom these values were significantly or moderately abnormal to determine the values' relationship to statin therapy and outcomes.
Results During the year of the study, 1014 (85%) of the 1194 patients who had a statin on their medication list had at least 1 monitoring test performed. Of these 1014 patients, 10 (1.0%) had a significant elevation and 5 (0.5%) a moderate elevation of transaminase levels, but none of these abnormalities appeared to be related to statin use. Moreover, 6 (0.9%) patients had at least 1 significantly abnormal CK value but it did not appear to be attributable to a statin; and of the 14 (2.1%) patients who had a moderate CK elevation, it was potentially due to a statin in only 2. There were no documented adverse sequelae associated with these abnormal results.
Conclusions In this study of statin use in a primary care practice, routine monitoring revealed no cases of significantly or moderately abnormal transaminase values attributable to statins. No significantly abnormal and only 2 moderately abnormal CK values were potentially attributable to statin use. This study questions the usefulness of routine measurement of transaminase and CK levels in all patients taking statins.
From the Department of Medicine (Drs Smith, Bernstein, Davis, Rind, and Shmerling), and the Divisions of General Medicine and Primary Care (Drs Smith, Bernstein, Davis, and Rind) and Rheumatology (Dr Shmerling), Beth Israel Deaconess Medical Center, Boston, Mass.
RELATED ARTICLE
Safety and Statin Therapy: Reconsidering the Risks and Benefits
Antonio M. Gotto, Jr
Arch Intern Med. 2003;163(6):657-659.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers
Sakamoto et al.
FASEB J. 2007;21:4087-4094.
ABSTRACT
| FULL TEXT
Use of maximum-dose simvastatin or atorvastatin in an ethnically diverse population
Song et al.
Am J Health Syst Pharm 2007;64:767-772.
ABSTRACT
| FULL TEXT
Risks Associated With Statin Therapy: A Systematic Overview of Randomized Clinical Trials
Kashani et al.
Circulation 2006;114:2788-2797.
ABSTRACT
| FULL TEXT
Improved therapeutic monitoring with several interventions: a randomized trial.
Feldstein et al.
Arch Intern Med 2006;166:1848-1854.
ABSTRACT
| FULL TEXT
Underappreciated Statin-Induced Myopathic Weakness Causes Disability
Dobkin
Neurorehabil Neural Repair 2005;19:259-263.
ABSTRACT
Potential Adverse Effects of Statins on Muscle
Tomlinson and Mangione
ptjournal 2005;85:459-465.
FULL TEXT
Role of statin therapy in the coronary bypass patient
Lazar
Ann. Thorac. Surg. 2004;78:730-740.
ABSTRACT
| FULL TEXT
Pharmacologic Lipid-Lowering Therapy in Type 2 Diabetes Mellitus: Background Paper for the American College of Physicians
Vijan and Hayward
ANN INTERN MED 2004;140:650-658.
ABSTRACT
| FULL TEXT
The Toxicology of HMG--CoA Reductase Inhibitors: Prediction of Human Risk
MacDonald and Halleck
Toxicol Pathol 2004;32:26-41.
ABSTRACT
Rhabdomyolysis and Renal Failure Associated with Gemfibrozil Monotherapy
Layne et al.
The Annals of Pharmacotherapy 2004;38:232-234.
ABSTRACT
| FULL TEXT
Monitoring drug treatment
Pirmohamed and Ferner
BMJ 2003;327:1179-1181.
FULL TEXT
Minerva
BMJ 2003;327:E235-235.
FULL TEXT
JournalScan
Malik
Heart 2003;89:815-816.
FULL TEXT
How Often to Screen for Statin-Related Toxicity
Journal Watch Cardiology 2003;2003:3-3.
FULL TEXT
Transaminase and CK Screening in Patients Who Take Statins
JWatch General 2003;2003:4-4.
FULL TEXT
Minerva
BMJ 2003;326:830-830.
FULL TEXT
Safety and Statin Therapy: Reconsidering the Risks and Benefits
Gotto
Arch Intern Med 2003;163:657-659.
FULL TEXT
|
